{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T16:15:23Z","timestamp":1777479323075,"version":"3.51.4"},"reference-count":31,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Clin Appl Thromb Hemost"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Indobufen reversibly inhibits platelet aggregation and has potential efficacy in acute coronary syndrome and long-term cardiovascular prevention. As an alternative treatment for patients intolerant to other antiplatelet drugs, evidence-based medicine is insufficient. The purpose of this study was to evaluate the efficacy and safety of indobufen therapy in patients with coronary artery disease, and to provide reference for expanded clinical use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a systematic review and meta-analysis of studies from the establishment of PubMed, EMBASE and other databases until their publication on November 21, 2024 The primary endpoints were major adverse cardiovascular and cerebrovascular events (MACCE), the primary safety index was the rate of hemorrhage of the Academic Research Consortium type 2, 3, or 5. The risk of ischemic stroke and myocardial infarction were used as the secondary indexes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      This meta-analysis included eight studies with a total of 13,545 patients. According to subgroup analysis, there was no significant difference in the incidence of unconscious-cerebrovascular events between indobufen monotherapy and dual antiplatelet agents (OR 1.02, 95%CI 0.84-1.23,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.84,\n                      <jats:italic>\n                        I\n                        <jats:sup>2<\/jats:sup>\n                      <\/jats:italic>\n                      \u2009=\u200948%). Indobufen reduced the bleeding risk in patients with coronary artery disease (OR 0.66, 95%CI 0.51-0.85,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u2009.001,\n                      <jats:italic>\n                        I\n                        <jats:sup>2<\/jats:sup>\n                      <\/jats:italic>\n                      \u2009=\u20090%). The risk of ischemic stroke for secondary indicators was comparable (OR 0.98, 95%CI 0.63-1.52,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.92,\n                      <jats:italic>\n                        I\n                        <jats:sup>2<\/jats:sup>\n                      <\/jats:italic>\n                      \u2009=\u20093%). Similarly, the risk of myocardial infarction was comparable (OR 0.61, 95%CI 0.35-1.09,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u2009.10,\n                      <jats:italic>\n                        I\n                        <jats:sup>2<\/jats:sup>\n                      <\/jats:italic>\n                      \u2009=\u20090%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>According to the results of this meta-analysis, indobufen based treatment may reduce the bleeding risk with better efficacy than dual antiplatelet agents for the patients with coronary artery disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10760296251381311","type":"journal-article","created":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T15:03:26Z","timestamp":1758639806000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and Safety of Indobufen in Patients with Coronary Artery Disease: A Systematic Review and Meta-Analysis"],"prefix":"10.1177","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-0491-1735","authenticated-orcid":false,"given":"Xiao-hong","family":"Wu","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Xiamen Haicang Hospital, Xiamen, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-8540-1286","authenticated-orcid":false,"given":"Xiao-yun","family":"Ye","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Xiamen Haicang Hospital, Xiamen, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3382-911X","authenticated-orcid":false,"given":"Si-heng","family":"Lian","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Xiamen Haicang Hospital, Xiamen, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3763-6327","authenticated-orcid":false,"given":"Xian-ni","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Xiamen Haicang Hospital, Xiamen, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4408-8034","authenticated-orcid":false,"given":"Ting-ting","family":"Nan","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Xiamen Haicang Hospital, Xiamen, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-7564-1873","authenticated-orcid":false,"given":"Yong-long","family":"Su","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Xiamen Haicang Hospital, Xiamen, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7044-2196","authenticated-orcid":false,"given":"Rui-na","family":"Cai","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Xiamen Haicang Hospital, Xiamen, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-9862-8392","authenticated-orcid":false,"given":"Yu-mei","family":"Cai","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Xiamen Haicang Hospital, Xiamen, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1302-0022","authenticated-orcid":false,"given":"Jin-bao","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Xiamen Haicang Hospital, Xiamen, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2025,9,23]]},"reference":[{"issue":"12","key":"e_1_3_3_2_2","first-page":"1000","article-title":"Chinese Guidelines for primary prevention of cardiovascular diseases J","volume":"48","author":"Chinese Society of Cardiology, Chinese Society of Rehabilitation, Chinese Society of Cardiology Prevention and Rehabilitation, Chinese Gerontology and geriatric Society of Cardiology, etc","year":"2020","unstructured":"Chinese Society of Cardiology, Chinese Society of Rehabilitation, Chinese Society of Cardiology Prevention and Rehabilitation, Chinese Gerontology and geriatric Society of Cardiology, etc. Chinese Guidelines for primary prevention of cardiovascular diseases J. Chinese Journal of Cardiovascular Diseases. 2020;48(12):1000\u20131039. (in Chinese).","journal-title":"Chinese Journal of Cardiovascular Diseases"},{"issue":"7","key":"e_1_3_3_3_2","first-page":"481","article-title":"China Cardiovascular health and disease report 2021","volume":"30","author":"Liyuan M","year":"2022","unstructured":"Liyuan M, Wang ZW, Jing F, et al. China Cardiovascular health and disease report 2021. Chinese Journal of Interventional Cardiology. 2022;30(7):481\u2013496. (in Chinese).","journal-title":"Chinese Journal of Interventional Cardiology"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2017.03.057"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.03.512"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehx419"},{"key":"e_1_3_3_7_2","article-title":"Expert consensus on diagnosis and treatment of patients with intolerance and low responsiveness to commonly used oral antiplatelet drugs J\/OL","volume":"4","author":"Huo Y","year":"2021","unstructured":"Huo Y, Wang YJ, Gu YQ, et al. Expert consensus on diagnosis and treatment of patients with intolerance and low responsiveness to commonly used oral antiplatelet drugs J\/OL. Chinese Journal of Cardiovascular Diseases. 2021;4:e1000076(2021-05-21). www.cvjc.org.cn\/index.php\/Column\/columncon\/articleid\/244. doi:https:\/\/doi.org\/10.3760\/cma.j.cn116031.2021.1000076. ISSN 2096-1586.","journal-title":"Chinese Journal of Cardiovascular Diseases"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2024.1412944"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000100"},{"key":"e_1_3_3_10_2","unstructured":"ChiCtr. A randomized controlled trial of indobufen versus aspirin plus dabigatran after stable coronary artery disease in atrial fibrillation [Trial registry record] (2020). Available online at: https:\/\/trialsearchwhoint\/Trial2aspx?TrialID=ChiCTR2000029015(Accessed March 22 2024)."},{"key":"e_1_3_3_11_2","unstructured":"ChiCtr. A randomized controlled study of indobufen and aspirin in the prevention of 1-year restenosis after off-pump coronary artery bypass [Trial registry record] (2021). Available online at: https:\/\/trialsearchwhoint\/Trial2aspx?TrialID=ChiCTR2100051267 (Accessed March 22 2024)."},{"key":"e_1_3_3_12_2","unstructured":"Nct. Effect of Indobufen and Aspirin on Platelet Aggregation and Long Term Prognosis in Patients With Coronary Heart Disease [Trial registry record] (2020). Available online at:https:\/\/clinicaltrialsgov\/show\/NCT04308551 (Accessed March 22 2024)."},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.950719"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.87.1.162"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5223(94)70392-2"},{"issue":"3","key":"e_1_3_3_16_2","first-page":"183","article-title":"Clopidogrel plus indobufen in acute coronary syndrome patients with hypersensitivity to aspirin undergoing percutaneous coronary intervention","volume":"24","author":"Francesco B","unstructured":"Francesco B, Fabio MP, Enrico M, et al. Clopidogrel plus indobufen in acute coronary syndrome patients with hypersensitivity to aspirin undergoing percutaneous coronary intervention. Platelets. May 2013;24(3):183\u2013188.","journal-title":"Platelets"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-021-03177-y"},{"issue":"5","key":"e_1_3_3_18_2","first-page":"466","article-title":"A randomized controlled trial of indobufen versus aspirin in the prevention of bridging restenosis after coronary artery bypass grafting","volume":"50","author":"Bai C","year":"2022","unstructured":"Bai C, Li JX, Yu Y, et al. A randomized controlled trial of indobufen versus aspirin in the prevention of bridging restenosis after coronary artery bypass grafting. Chin J Cardiol. 2022;50(5):466\u2013470. Chinese. doi:https:\/\/doi.org\/10.3760\/cma.j.cn112148-20210701-00560.","journal-title":"Chin J Cardiol"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.122.062762"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-024-03374-3"},{"issue":"1","key":"e_1_3_3_21_2","first-page":"1,2364748","article-title":"The safety and efficacy of indobufen or aspirin combined with clopidogrel in patients with acute myocardial infarction after percutaneous coronary intervention","volume":"2024","author":"Dai W-B","unstructured":"Dai W-B, Ren J-Y, Hu S-T, et al. The safety and efficacy of indobufen or aspirin combined with clopidogrel in patients with acute myocardial infarction after percutaneous coronary intervention. Platelets. 2024; 35(1):1,2364748.","journal-title":"Platelets"},{"issue":"04","key":"e_1_3_3_22_2","first-page":"359","article-title":"Efficacy and safety of indobufen tablets for prevention and treatment of ischemic cardio-cerebrovascular disease:A meta-analysis","volume":"33","author":"Yang Xia LW","year":"2017","unstructured":"Yang Xia LW, Ken C, Shujie D, Suodi Z. Efficacy and safety of indobufen tablets for prevention and treatment of ischemic cardio-cerebrovascular disease:A meta-analysis. Chin J Clin Pharmacol. 2017;33(04):359\u2013362.","journal-title":"Chin J Clin Pharmacol"},{"issue":"05","key":"e_1_3_3_23_2","first-page":"532","article-title":"Meta-analysis of the efficacy and safety of indobufen in the prevention of cardiovascular and cerebrovascular events","volume":"9","author":"Xu Rongbin YJ","year":"2017","unstructured":"Xu Rongbin YJ, Shen H, Feng S, Jun M. Meta-analysis of the efficacy and safety of indobufen in the prevention of cardiovascular and cerebrovascular events. Chin J Evid-Based Cardiovasc Med. 2017;9(05):532\u2013538.","journal-title":"Chin J Evid-Based Cardiovasc Med"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1650306"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1097\/00045391-200403000-00004"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2004.08.070"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-016-8181-5"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.20356"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002512-200118050-00007"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11481-020-09978-9"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehad191"},{"issue":"10","key":"e_1_3_3_32_2","article-title":"Duration of dual antiplatelet therapy: A systematic review for the 2016 ACC\/AHA guideline focused update on duration of dual anti-platelet therapy in patients with coronary artery disease: A report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines","volume":"134","author":"Review Committee Members E","unstructured":"Review Committee Members E, Bittl JA, Baber U, Bradley SM. Duration of dual antiplatelet therapy: A systematic review for the 2016 ACC\/AHA guideline focused update on duration of dual anti-platelet therapy in patients with coronary artery disease: A report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines. Circulation. 2016; 134(10):e156\u2013e178.","journal-title":"Circulation"}],"container-title":["Clinical and Applied Thrombosis\/Hemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10760296251381311","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10760296251381311","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10760296251381311","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:05:23Z","timestamp":1777385123000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10760296251381311"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":31,"alternative-id":["10.1177\/10760296251381311"],"URL":"https:\/\/doi.org\/10.1177\/10760296251381311","relation":{},"ISSN":["1076-0296","1938-2723"],"issn-type":[{"value":"1076-0296","type":"print"},{"value":"1938-2723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8]]},"article-number":"10760296251381311"}}